TG Therapeutics, Inc. (TGTX) Reaches $9.88 After 9.00% Down Move; 6 Analysts Bullish PolyOne (POL)

January 14, 2018 - By Richard Conner

Among 9 analysts covering Polyone Corporation (NYSE:POL), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Polyone Corporation had 23 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of PolyOne Corporation (NYSE:POL) has “Hold” rating given on Thursday, February 4 by Wellington Shields. On Thursday, June 15 the stock rating was maintained by Jefferies with “Hold”. The stock of PolyOne Corporation (NYSE:POL) earned “Buy” rating by Robert W. Baird on Monday, August 24. Jefferies maintained PolyOne Corporation (NYSE:POL) on Wednesday, October 25 with “Hold” rating. KeyBanc Capital Markets maintained the stock with “Overweight” rating in Monday, April 4 report. Jefferies maintained it with “Hold” rating and $4200 target in Friday, August 4 report. The firm earned “Hold” rating on Friday, June 30 by Jefferies. The rating was downgraded by Longbow to “Neutral” on Tuesday, July 28. The rating was upgraded by Seaport Global on Monday, April 18 to “Buy”. The stock of PolyOne Corporation (NYSE:POL) earned “Hold” rating by Jefferies on Friday, September 15. See PolyOne Corporation (NYSE:POL) latest ratings:

31/10/2017 Broker: SunTrust Rating: Buy New Target: $49.0
25/10/2017 Broker: Jefferies Rating: Hold New Target: $45.0 Maintain
26/10/2017 Broker: KeyBanc Capital Markets Rating: Overweight Old Target: $43 New Target: $47 Maintain
17/10/2017 Broker: Jefferies Rating: Hold New Target: $42.0 Maintain
10/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $42.0 Maintain
15/09/2017 Broker: Jefferies Rating: Hold New Target: $42.0 Maintain
16/08/2017 Broker: Oppenheimer Rating: Buy New Target: $43.0 Initiate
04/08/2017 Broker: Jefferies Rating: Hold New Target: $42.0000 Maintain

The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) is a huge mover today! The stock decreased 7.28% or $0.775 during the last trading session, reaching $9.875. About 2.10 million shares traded or 43.21% up from the average. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since January 14, 2017 and is uptrending. It has outperformed by 43.84% the S&P500.The move comes after 8 months negative chart setup for the $697.69M company. It was reported on Jan, 14 by Barchart.com. We have $8.99 PT which if reached, will make NASDAQ:TGTX worth $62.79 million less.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $697.69 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 17 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright with “Buy” on Wednesday, August 12. Zacks upgraded it to “Hold” rating and $19 target in Wednesday, August 12 report. FBR Capital maintained the stock with “Buy” rating in Monday, December 11 report. On Tuesday, December 1 the stock rating was initiated by FBR Capital with “Outperform”. The firm has “Buy” rating given on Friday, May 27 by Suntrust Robinson. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by Brean Capital on Thursday, October 6. On Monday, June 5 the stock rating was maintained by Jefferies with “Buy”. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Thursday, June 15 with “Buy” rating. The stock has “Strong Buy” rating by Raymond James on Wednesday, September 9. The firm earned “Buy” rating on Tuesday, March 7 by H.C. Wainwright.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on March, 9. They expect $-0.46 earnings per share, up 4.17% or $0.02 from last year’s $-0.48 per share. After $-0.48 actual earnings per share reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -4.17% EPS growth.

Since December 29, 2017, it had 0 insider buys, and 1 insider sale for $272,051 activity. Power Sean A also sold $272,051 worth of TG Therapeutics, Inc. (NASDAQ:TGTX) shares.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 1.07, from 2.28 in 2017Q2. It fall, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported. Raymond James & Associates has invested 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Manufacturers Life Insur The holds 0% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 36,397 shares. Credit Suisse Ag, a Switzerland-based fund reported 224,066 shares. 71,998 are held by Stoneridge Invest Prtnrs Limited Liability Com. Sectoral Asset Management holds 0.15% or 100,366 shares. Hanson Mcclain Inc has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 62 shares. Employees Retirement Association Of Colorado has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Savings Bank Of Ny Mellon reported 298,649 shares. National Bank & Trust Of America Corporation De holds 9,998 shares. California Employees Retirement System invested in 0% or 106,400 shares. 308,120 are owned by Eam Invsts Limited Liability Com. Susquehanna Intll Group Incorporated Ltd Liability Partnership stated it has 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). 30,247 were reported by Metropolitan Life Ins Ny. D E Shaw reported 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Hightower Advisors Lc invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX).

PolyOne Corporation provides specialized polymer materials, services and solutions in the United States and internationally. The company has market cap of $3.69 billion. The Company’s Color, Additives, and Inks segment offers specialized color and additive concentrates in solid and liquid form for thermoplastics; dispersions for thermosets; and specialty inks, plastisols, and vinyl slush molding solutions. It currently has negative earnings. The companyÂ’s Specialty Engineered Materials segment provides specialty polymer formulations, services, and solutions for designers, assemblers, and processors of thermoplastic materials; and long glass and carbon fiber technology, and thermoset and thermoplastic composites.

Investors sentiment increased to 0.99 in Q3 2017. Its up 0.06, from 0.93 in 2017Q2. It increased, as 26 investors sold PolyOne Corporation shares while 74 reduced holdings. 25 funds opened positions while 74 raised stakes. 72.65 million shares or 1.67% less from 73.89 million shares in 2017Q2 were reported. Product Ptnrs Ltd Company invested in 89,411 shares. Adams Diversified Equity Fund Inc invested in 26,200 shares. Bank Of Montreal Can reported 1,023 shares. Advsr Asset Inc invested in 8,160 shares or 0.01% of the stock. Weaver C Barksdale & invested 0.02% of its portfolio in PolyOne Corporation (NYSE:POL). Aqr Ltd owns 348,643 shares. Bancshares Of New York Mellon has 1.29M shares for 0.01% of their portfolio. Icon Advisers stated it has 0.17% in PolyOne Corporation (NYSE:POL). Renaissance Techs Ltd Liability Co reported 303,758 shares. Channing Cap Limited Com invested in 2.02 million shares or 3.05% of the stock. Jfs Wealth Advsr Ltd Liability Corp accumulated 0% or 7 shares. Congress Asset Mgmt Ma reported 0.06% in PolyOne Corporation (NYSE:POL). First Advsrs L P owns 47,995 shares. Comerica Commercial Bank reported 163,977 shares stake. Rothschild Asset Mgmt has invested 0.34% in PolyOne Corporation (NYSE:POL).

The stock decreased 1.25% or $0.58 during the last trading session, reaching $45.65. About 299,753 shares traded. PolyOne Corporation (NYSE:POL) has risen 5.26% since January 14, 2017 and is uptrending. It has underperformed by 11.44% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: